Velcade uses "iPatient" to spur sales

Share this article:
Velcade uses "iPatient" to spur sales
Velcade uses "iPatient" to spur sales

Velcade has been the market leader for the blood cancer myeloma since its 2003 introduction. Ten years and two competitive entrants later, Velcade is no longer alone at the top and has rolled out an “iPatient” sales aid.

“We saw two competitors, Kyprolis and Pomalyst, roll out in the past year,” says Philip Prince, senior product manager, Velcade marketing at Millennium Takeda. “We really wanted to invigorate the brand.”

The app continues last year's professional print campaign, with the tagline “Survival never gets old.” The iPatient sales aid offers four patient case studies as discussion points as well as other information to clarify who should be prescribed Velcade.

It's Takeda Millennium's second iPad app, but it's their first that “takes physicians through the patient journey with provocative case studies,” Prince said.

While the drug boasts strong efficacy, Velcade, as an IV treatment, also has debilitating side effects like peripheral neuropathy. Velcade was approved by FDA for subcutaneous administration in January 2012.

“With the launch of the subcutaneous route, we found through market research that physicians were developing a stronger emotional connection with Velcade based on a new ‘softer' perception—thanks to the different side-effect profile,” says Prince. “This change in perception allowed us to introduce a patient-focused campaign.”

So far, the move appears to have paid off: “With the launch of the iPatient App to our sales force at a recent congress, we more than doubled our targeted discussion length with physicians,” said Prince.

Millennium worked with Toronto-based digital agency Klick Health on the project. Klick also helped them develop an unbranded website earlier this year at mymultiplemyeloma.com.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets